Summary Antibody-dependent cellular cytotoxicity (ADCC) is considered to be the major mechanism through which tumour cells, upon treatment with anti-tumour MAbs, are eliminated in vivo. However, the relative importance of various parameters that influence the efficacy of ADCC is unclear. Here we present in vitro data on the impact of MAb affinity and antigen density on ADCC, as obtained by comparison of two MAbs against the tumour-associated antigen Ep-CAM. The low-affinity MAb 17-1A (Ka = 5 x 107 M-1) currently used for therapy, and the highaffinity MAb 323/A3 (Ka = 2 x 109 M-1), were compared in ADCC experiments against murine and human tumour target cells transfected with the Ep-CAM cDNA under the control of an inducible promoter to enable regulation of the target antigen expression levels. Data obtained from these studies revealed that the high-affinity MAb, in contrast to the low-affinity MAb, could mediate killing of tumour cells with low antigen expression levels. Even at comparable MAb-binding levels, ADCC mediated by the high-affinity MAb was more effective. The kinetics of ADCC was also found to be determined by the level of antigen expression, and by the affinity and the concentration of the MAb used. The efficacy of ADCC with both low-and high-affinity MAbs further depended on adhesive interactions between effector and target cells mediated by CD1 8. However, at every given MAb concentration these interactions were of less importance for the high-affinity MAb than for the lowaffinity MAb. As heterogeneity of a target antigen expression is a common feature of all tumours, and some tumour cells express very low levels of the antigen, the use of high-affinity MAbs in immunotherapy may significantly improve the clinical results obtained to the present date in the treatment of minimal residual disease.
A wide range of monoclonal antibodies (MAbs) against tumourassociated antigens is available to combat various forms of human neoplasia. Application of such unconjugated MAbs in an immunotherapeutic setting can only be effective if all tumour cells express the targeted antigen in amounts that allow sufficient binding of MAb to trigger the effector mechanisms that eliminate the tumour cells (Herlyn et al, 1985) . When patients with minimal residual disease, after surgery of Dukes' C colon carcinoma, were treated with MAb 17-lA, a reduction in the 5-year mortality of 30% was observed compared with a control group (Riethmuller et al, 1994) . Although the increase in the 5-year survival obtained in this trial is clinically very important, the results might be improved with a better understanding of the parameters that play a role in the antibody-mediated interactions between the target cell and the effector mechanisms.
Antibody-mediated effector mechanisms against tumour cells, of which the activity has been shown in vitro, are antibody-dependent cellular cytotoxicity (ADCC) (Steplewski et al, 1988 ; Herlyn and Koprowski, 1982) and complement-mediated cytotoxicity (Orlandi et al, 1992; Velders et al, 1994) . The presence in tumours, surgically removed from MAb-treated patients, of infiltrating natural killer cells and of macrophages (Adams et al, 1984; Shetye et al, 1988) as well as of complement deposits (Adams et al, 1984) , suggests that both ADCC and complement-mediated cytotoxicity may play a role in tumour cell destruction in vivo. However, as most tumour cells express increased amounts of complement-inhibiting regulators which protect the cells against lysis by autologous complement (Kumar et al, 1993; Gorter et al, 1996) , the main anti-tumour mechanism of therapeutic antibodies in vivo is considered to be ADCC. The impact of antigen density and antibody affinity on the efficacy of tumour cell elimination via ADCC is relatively poorly studied, mainly because of the lack of adequate models.
In the clinical trial mentioned above (Riethmuller et al, 1994) , the epithelial cell adhesion molecule (Ep-CAM) (Litvinov et al, 1994 a,b; 1995) , a human 40-kDa epithelial glycoprotein, and one of the most frequently targeted tumour-associated antigens, was the target antigen for the murine MAb 17-1A. This MAb has been recently approved in Germany as a therapeutic reagent for the treatment of Dukes' C colorectal cancer; this indicates that Ep-CAM as a target antigen has a future in immunotherapy. Therefore, in the present study on factors defining the efficacy of ADCC, we have chosen Ep-CAM as the target antigen. Ep-CAM was targeted by MAbs 17-lA and 323/A3, which recognize overlapping epitopes on the Ep-CAM molecule and compete for binding to EP-CAM. The 323/A3 MAb affinity for Ep-CAM was found to be 40-fold higher than the affinity of MAb 17-lA (Pak et al, 1991; Velders et al, 1994; 1996) . To obtain model cell lines, in which the surface expression of Ep-CAM could be varied, the Ep-CAM cDNA was introduced into Ep-CAM-negative murine and human cell lines under the transcriptional control of an inducible promoter. *Present address: Cardinal Bernardin Cancer Center. Loyola University Chicago.
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The results of this study demonstrate that the efficacy and kinetics of ADCC are determined by both antibody affinity and antigen density. In addition, ADCC was shown to be dependent on LFA-I -mediated interactions, however the high-affinity MAb 323/A3 was to a lesser extent dependent on these interactions than the low-affinity MAb 17-1A. 
MATERIALS AND METHODS Antibodies
For all in vitro experiments with human effector cells the chimeric human/mouse versions of the antibodies 17-1A and 323/A3 were used (Sun et al, 1987; Velders et al, 1994) . The chimeric antibodies contain the same human IgG 1 and kappa-constant domains as both MAbs were chimerized at Centocor using identical methods and vectors. All antibodies were initially purified over protein ASepharose (Pharmacia, Woerden, The Netherlands), and were further purified by sequential ion-exchange chromatography on Mono S and Mono Q (Pharmacia) columns, followed by diafiltration into phosphate-buffered saline (PBS). All antibody preparations were tested using LAL assays and shown to be endotoxin negative. The anti-human CD18, clone 7E4 (Immunotech, Marseilles, France), was used in ADCC inhibition assays. To quantify the MAb binding to Ep-CAM using flow cytometry, the Fab fragments of the chimeric 323/A3 and 17-1A MAbs, directly labelled with FLUOS (Boehringer Mannheim, Mannheim, Germany), were used.
Cell lines
The SV40 immortalized human breast epithelial cell line HBL 100, clone HCA (kindly provided by Dr J Hilkens, NKI, Amsterdam, The Netherlands), the mouse mammary carcinoma cell line L153S (Litvinov et al, 1994a ) and the transfectants HCA-M and C 1.5 and C 1.13 were all cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (Gibco-BRL, Paisley, UK). 50 gg ml-' streptomycin and 50 tg ml-' penicillin at 37°C and 5% carbon dioxide.
Generation of Ep-CAM transfected cells
For the generation of Ep-CAM-expressing murine L153 cells the SmaI/BglII fragment of the GA733-2 Ep-CAM cDNA (Szala et al, 1990 ) was subcloned into the pJSQ eukaryotic expression vector ( Morgenstern and Land, 1990) under the transcriptional control of the dexamethasone inducible promotor of the MMTV LTR. Two clones, C 1.5 and C 1.13, were used for this study. For the generation of Ep-CAM-expressing human HCA cells, the Ep-CAM cDNA was cloned into the pMEP4 expression vector (Invitrogen, Leek, The Netherlands), under the control of the inducible metallothionein promoter; the Ep-CAM-transfected HCA cell line is referred to as HCA-M. Transfection of both human and murine cells was performed using DOTAP (Boehringer Mannheim) as previously described (Litvinov et al, 1994a) . After selection with the appropriate antibiotic, Ep-CAM expression of selected clones was identified using FACS analysis with MAb 323/A3. Induction of Ep-CAM expression in HCA-M or C1.5 and C1. (Figure 2 ) with activated human PBLs and chimeric c323/A3 or c17-lA MAbs. The treatment of target cells with dexamethasone did not increase the susceptibility of cells to ADCC, as was tested using a control L153S transfectant containing Ep-CAM cDNA in the pJ3Q expression vector under the control of the constitutive SV40 promotor (data not shown). No lysis was observed for C1.5 and C1.13 cells (data not shown) by activated human PBLs in the absence of ADCC-mediating antibodies.
In the presence of antibody, the cells with induced Ep-CAM expression were killed better in ADCC with MAbs c 17-lA ( Figure  2A ) and c323/A3 ( Figure 2B ) than their uninduced counterparts. Moreover, C1.5 cells, which express higher Ep-CAM levels than C 1.13 cells both before and after induction of Ep-CAM ( Figure   IA .)_ C) B when mediated by MAb c323/A3 was higher than lysis mediated by MAb c17-lA. These experiments, with the data presented in Figure 2A and B, show that cell lysis by ADCC is dependent on the total amount of antibody bound to the cells but also on antibody affinity. ADCC with murine targets was performed using human effector cells. In a combination of effector and target, one may expect a decrease, if not a complete exclusion (Mentzer et al, 1986; Johnston et al, 1990) , of the adhesive interactions between the effector and target cell. The impact of MAb affinity and antigen expression levels on ADCC, in the presence of accessory adhesion molecules on the target cells and the matching counterparts on the effector cells, was studied using human PBLs against transfected human HCA-M target cells with inducible Ep-CAM expression. ADCC assays (Figure 3) and FACscan analysis for Ep-CAM expression levels and MAb binding ( Figure IB) were carried out in parallel. Again, in all experiments, MAb c323/A3 consistently mediated higher lysis than MAb 17-1A (compare the lysis levels at the 4-h time point in Figure 3 ).
ADCC kinetics and MAb affinity
The kinetics of the ADCC reaction was investigated using human PBLs and . As ADCC is considered to be the major mechanism of MAb action in therapy (Adams et al, 1984) , we performed this study on the importance of antigen density and MAb affinity for ADCC efficacy. In contrast to other studies in this field (Capone et al, 1984; Hagan et al, 1986; (Velders et al, 1995 (Velders et al, 1996) . In agreement with Herlyn et al. (1985) , our results, as presented in Figure 2, (Velders et al, 1996) The requirement of accessory adhesions between effector and target for ADCC is not very clear, however the scope of the publications on the subject suggests their importance (Liesveld et al, 1991; Webb et al, 1991; Edwards et al, 1992 ; Kushner and Cheung, 1992 [owing to their chimerization using the same genes for the constant Ig chains (Sun et al, 1987; Velders et al, 1994) ], it is the affinity of the antibody to the target antigen or the three-dimensional orientation of Fc tails that is of importance. From the results presented in Figure 4 we conclude that high MAb affinity, or a large number of antibody-antigen interconnections between effector and target cells, may well compensate the reducing effect on ADCC of the suppressed accessory interactions. Knowledge of the kinetics of the ADCC reaction with different MAbs could also help when choosing MAbs for immunotherapy. We provided evidence that, against the same HCA-M cells, the high-affinity MAb 323/A3 not only mediated higher lysis, but also continued to mediate cell lysis for an extended period, whereas an extended incubation with MAb 17-1A had no additional effect. The observed lack of plateau values in ADCC in a 5 h assay against human target cells with MAb 323/A3, and the overall higher lysis levels obtained, indicates that MAb 323/A3 can mediate the killing of Ep-CAM-expressing tumour cells that cannot be killed by MAb 17-lA, which is in agreement with our previous in vivo results (Velders et al, 1996) . It seems plausible that only the cells with the highest levels of Ep-CAM expression were killed by the 17-1A MAb, and that cells with lower levels of expression were not lysed. However, such cells could be lysed by the 323/A3 MAb. Based on our previous in vivo results and the data presented here, we conclude that the high-affinity 323/A3 MAb can eliminate substantially more cells from a heterogeneous tumour cell population than the low-affinity MAb 17-1A. It's also possible that low Ep-CAM-expressing tumour cells in patients may be more effectively eradicated using the high-affinity MAb 323/A3 instead of MAb 17-1 A. ABBREVIATIONS ADCC, antibody dependent cellular cytotoxicity; Ep-CAM, epithelial cell adhesion molecule; i.p., intraperitoneal; s.c., subcutaneous; LTR, long terminal repeat; MAb, monoclonal antibody; MMTV, murine mammary tumour virus; PBLS, peripheral blood lymphocytes.
